The direct costs of HIV/AIDS care (Q34497622)

2 August 2017

1 reference

title

The direct costs of HIV/AIDS care (English)

1 reference

2 August 2017

1 reference

Robert S Hogg

4

0 references

Karissa M. Johnston

3

object named as

Karissa M Johnston

1 reference

2 August 2017

8

Julio S Montaner

1 reference

2 August 2017

7

Boris Sobolev

1 reference

2 August 2017

Adrian R Levy

1

1 reference

2 August 2017

Douglas James

2

1 reference

2 August 2017

P Richard Harrigan

5

1 reference

2 August 2017

Brian P Harrigan

6

1 reference

2 August 2017

1 March 2006

1 reference

Lancet Infectious Diseases

2 August 2017

1 reference

2 August 2017

6

1 reference

2 August 2017

3

1 reference

2 August 2017

171-177

1 reference

Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study

2 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970413-3

7 January 2021

Natural history of HIV infection in the era of combination antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970413-3

7 January 2021

Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. Fédération National des Centres de Lutte contre le SIDA

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970413-3

7 January 2021

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970413-3

7 January 2021

The cost of HIV treatment and care. A global review

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970413-3

7 January 2021

HIV patients in the HCUP database: a study of hospital utilization and costs.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970413-3

7 January 2021

Hospital and outpatient health services utilization among HIV-infected patients in care in 1999.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970413-3

7 January 2021

Impact of Practice Changes on an Antiretroviral Budget in an HIV Care Program

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970413-3

7 January 2021

The treatment and care costs of people with HIV infection or AIDS: development of a standardised cost framework for Europe

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970413-3

7 January 2021

Intensive injection cocaine use as the primary risk factor in the Vancouver HIV-1 epidemic

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970413-3

7 January 2021

Economic evaluation of HIV prevention programs

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970413-3

7 January 2021

Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970413-3

7 January 2021

Health economics in HIV disease. A review of the European literature

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970413-3

7 January 2021

A multicentre study of patient survival, disability, quality of life and cost of care: among patients with AIDS in northern Italy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970413-3

7 January 2021

Financing HIV service provision in England: estimated impact of the cost of antiretroviral combination therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970413-3

7 January 2021

Costs of HIV medical care in the era of highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970413-3

7 January 2021

Resource utilization and hospital cost of HIV/AIDS care in Italy in the era of highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970413-3

7 January 2021

Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970413-3

7 January 2021

Economic Notes: opportunity cost

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970413-3

7 January 2021

Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970413-3

7 January 2021

Enfuvirtide: first fusion inhibitor for treatment of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970413-3

7 January 2021

Enfuvirtide: a new class of antiretroviral therapy for HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970413-3

7 January 2021

How good are US studies of HIV costs of care?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970413-3

7 January 2021

10.1016/S1473-3099(06)70413-3

Identifiers

DOI

1 reference

2 August 2017

1 reference